
Gini Harrison
@giniharrison
Senior Lecturer @OU_Psychology. Interests: mental health & wellbeing, perinatal anxiety, psycho-oncology, eHealth, and applied cognitive psychology.
ID: 22022258
26-02-2009 15:41:27
395 Tweet
297 Followers
232 Following




So thrilled that Deborah James has got this recognition. Words fail me when it comes to the situation she is in, but my goodness⦠what a legacy!! Over Ā£3.5 million for charity and rising!! What an absolute star!! šš„°



The fabulous Son of Cormack at Lakefest. Definitely worth a listen!! Andy and I also feature in the interview. Fame at last!?! š




Dark day for #EGFR #exon20 pts when discussions betw. FDA Oncology & Takeda Oncology led to a decision re #mobocertinib's withdrawal (timing unclear). No words! We've worked w/mobo since early 2017 & need it to be available as one of our 2 anchor drugs. 844-662-8532 (Takeda info)

Lung cancer: Why non-smokers don't respond to treatments via ā¦Medical News Todayā© āAll you need to be at risk for lung cancer is to have lungs,ā Singhi told Medical News Today ā¦ā¦ medicalnewstoday.com/articles/why-mā¦

#ESMO24 Sanjay Popat presents an interim OS update for MARIPOSA-2 (amivantamab + chemotherapy vs chemotherapy in #EGFR mutant NSCLC post osimertinib). OS trend favors adding amivantamab (HR 0.73), not yet statistically significant. 18m OS rate 50% vs 40%. #ESMOAmbassadors


Prof Charles Swanton finds use of ctDNA in operable #lungcancer determines relapse at #ESMO24. Positive pre-operative ctDNA predicts odds of relapse. Should ctDNA use be standard in all operable cases? Will this inform treatment in future esp those w pre-operative ctDNA?




Osimertinib BEATEN!! MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%)āfirst combo to show OS superiority over SoC, extending OS beyond 3 years in 1L EGFRm NSCLC. #ESMOAmbassadors #ELCC25 ESMO - Eur. Oncology


Osimertinib after definitive chemoradiotherapy is a "new standard of care" in unresectable, stage III, EGFR-mutant NSCLC, reported Suresh S. Ramalingam, MD, FASCO of Winship Cancer Institute of Emory University in an updated analysis of the LAURA study presented at #ELCC25. #ELCC2025 #lcsm
